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Abstract: Small extracellular vesicles (EVs) are able to pass from the central nervous system (CNS)
into peripheral blood and contain molecule markers of their parental origin. The aim of our study was
to isolate and characterize total and neural-derived small EVs (NDEVs) and their micro RNA (miRNA)
cargo in Alzheimer’s disease (AD) patients. Small NDEVs were isolated from plasma in a population
consisting of 40 AD patients and 40 healthy subjects (CTRLs) using high throughput Advanced
TaqMan miRNA OpenArrays®, which enables the simultaneous determination of 754 miRNAs.
MiR-23a-3p, miR-223-3p, miR-100-3p and miR-190-5p showed a significant dysregulation in small
NDEVs from AD patients as compared with controls (1.16 ± 0.49 versus 7.54 ± 2.5, p = 0.026;
9.32 ± 2.27 versus 0.66 ± 0.18, p <0.0001; 0.069 ± 0.01 versus 0.5 ± 0.1, p < 0.0001 and 2.9 ± 1.2
versus 1.93 ± 0.9, p < 0.05, respectively). A further validation analysis confirmed that miR-23a-3p,
miR-223-3p and miR-190a-5p levels in small NDEVs from AD patients were significantly upregulated
as compared with controls (p = 0.008; p = 0.016; p = 0.003, respectively) whereas miR-100-3p levels
were significantly downregulated (p = 0.008). This is the first study that carries out the comparison
between total plasma small EV population and NDEVs, demonstrating the presence of a specific AD
NDEV miRNA signature.
Keywords: Alzheimer’s disease; extracellular vesicles (EVs); neural-derived extracellular vesicles
(NDEVs); microRNA
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1. Background
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by cognitive
decline and memory impairment. The neuropathological hallmarks include the deposition of senile
plaques resulting from the excessive accumulation of β-amyloid protein (Aβ) and the formation of
neurofibrillary tangles (NFTs) derived from hyperphosphorylated tau proteins leading globally to
neural dysfunction [1]. Increasing epidemiological evidence shows that there is a presymptomatic
long-lasting period for clinical incubation of the disease that could take several years before leading to
cognitive dysfunction. The long preclinical period of AD makes it necessary to seek robust and reliable
diagnostic biomarkers for early intervention. At present, diagnostic research criteria for AD [2] include
emission tomography (PET) with amyloid tracer, which is a complex and very expensive tool, and the
cerebrospinal fluid (CSF) pathogenic protein detection, that implies the invasive procedure of sample
collection by lumbar puncture. In this scenario, circulating biomarkers would be of help for differential
diagnosis and possibly for monitoring cognitive decline.
Promising candidates are small extracellular vesicles (EVs) that are extracellular membrane
vesicles of endosomal origin with a diameter ranging from 30 to 150 nm. Initially referred to as
“exosomes” by the international scientific community, they were later addressed by the International
Society for Extracellular Vesicles (ISEV) as “small EVs” [3]. They are produced by all cell types and
contain several molecular markers of their parental origin. They also include proteins, lipids and
nucleic acids, named EV “cargo”. The EV “cargo” varies depending on the physiological state of the
cell [4]. Cells from the central nervous system (CNS), neurons, astrocytes, oligodendrocytes are also
able to secrete small EVs into the extracellular compartment, both in physiological and pathological
conditions [5]. They could thus reflect the state of their neural cell of origin, an aspect that may
contribute to the diagnosis of neurodegenerative diseases [6]. In this regard, Fiandaca et al. were able
to isolate small neural-derived extracellular vesicles (NDEVs) from plasma using a combination of
chemical and immunochemical approaches based on specific antibody against neural L1 cell adhesion
molecule (L1CAM) and to evaluate their protein content [7]. This challenging approach for the isolation
of a specific subpopulation of vesicles has generated increasing interest in using small NDEVs as
a source for biomarkers in neurodegenerative diseases including AD [8–10]. The ability to analyze
the content of plasma small NDEVs has been demonstrated on several fronts to be relevant to AD
pathogenesis and also highlights the role of small NDEVs as promising biomarkers. This hypothesis
has also been supported by increasing evidence including levels of amyloid-β and tau proteins, as well
as the synaptic proteins [11] involved in AD pathogenesis.
As mentioned above, the EVs’ “cargo” also comprises nucleic acids such as RNA. This aspect also
generated an interest in the field of neurodegenerative disorders after the discovery of EVs as mediators
delivering microRNAs (miRNAs) in intercellular communication [12] or the source of miRNAs as
candidates for biomarkers of disease [13,14].
MiRNAs are endogenous small noncoding RNAs of 21–23nt in length that are capable of controlling
gene expression through post-transcriptional regulation. MiRNAs exert their regulatory effect by
suppressing translation of mRNA through the binding to the 3′-untranslated region (UTR) of target
mRNA or by degrading target mRNA. The same miRNA can target different mRNAs contemporarily,
whereas a single mRNA can be regulated by different miRNAs.
MiRNAs have been identified in many biological fluids, such as plasma, serum, CSF, urine [15],
highlighting their potential role as peripheral noninvasive biomarkers of several pathological conditions,
including cardiovascular diseases, cancer and neurodegenerative diseases [16,17]. A growing body
of evidence demonstrated that they are intimately involved in synaptic function and in specific
signals during memory development [15]. Moreover, in vivo experiments showed that Aβ and Tau
pathology drove the deregulation of some neuronal miRNAs (miR-142-5p, miR-146a-5p, miR-155-5p),
alterations confirmed also in AD patients [18]. MiRNAs could also have a predominant role in driving
the pathogenic process of the disease as it was shown that most altered miRNAs also target AD relevant
pathogenic proteins [19]. Several miRNAs have been robustly identified as deregulated in brain tissue
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from AD patients as recently reviewed in Herrera-Espejo et al. [20], whereas others were proposed as
circulating peripheral biomarkers of disease, although none of them had the same regulation status in
all studies [20].
Extracellular miRNAs in serum and plasma are found in different fractions [21]. Usually, they
are encapsulated in membrane vesicles or are released from apoptotic bodies [22]. Most circulating
miRNAs are, however, bound to proteins such as Argonaute2 [23].
The high heterogeneity of the results on circulating miRNAs levels in AD casts a shadow on their
real diagnostic potential. Moreover, the origin of circulating miRNAs is heterogeneous itself and likely
could not reflect the specific pathological status. Lastly, independent of the localization that could be
protein- or vesicle-bound, miRNAs in serum or plasma could hardly trace back their cellular origin.
In this scenario, small NDEVs could be considered a promising source of miRNAs that
could directly reflect the physiological condition of the nervous system without introducing
confounding factors.
It was already proven that EVs represented an enriched source of noncoding RNAs of different
types, such as miRNAs, that, in this way, result protected from RNase degradation. This peculiar
aspect represents the solid foundation for their clinical application as diagnostic biomarkers.
Moreover, the process of packaging of miRNAs into small EVs in cytoplasm is a finely regulated
event that includes multiple steps, supporting the active functional role of miRNAs in these vesicles.
MiRNAs released from EVs could modulate the expression and function of amyloid precursor
protein and tau proteins. EV-carried miRNAs could drive, via Toll-like receptors, inflammatory processes
in AD and may also regulate neuroplasticity to relieve neurological damage [24].
Moreover, Lugli et al. found a consistent dysregulation of miRNA levels in plasma-derived EVs
from AD patients pointing out a specific signature of seven miRNAs that were able to predict the group
identity [12].
Given these premises, herein we carried out a comprehensive characterization of small NDEVs
and a further analysis of their miRNA content for the detection of possible dysregulated miRNAs
in patients with AD. We evaluated simultaneously miRNAs content from total plasma small EVs
and small NDEVs to be certain of specifically isolating those of neuronal derivation from the others
deriving from the total small EVs population.
Our final goal was to detect a specific small NDEVs miRNA signature in plasma from patients
with AD. Assuming that pathogenic alterations in such NDEVs may reflect the brain environment,
this research could lead to the identification of potential reliable peripheral biomarkers for early
diagnosis of the disease.
2. Methods
2.1. Study Design and Sample Collection
Forty patients with AD were recruited at the Alzheimer Center of the University of Milan,
Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, between 2015 and 2017. All patients
underwent a clinical interview, neurological and neuropsychological examination, routine blood tests,
brain MRI and lumbar puncture (LP) for quantification of the CSF biomarkers Aβ, total tau and
tau phosphorylated at position 181 (Ptau). Cut-off thresholds of normality were: Aβ ≥ 600 pg/mL;
tau ≤ 500 pg/mL for individuals older than 70 years and ≤450 pg/mL for individuals aged between 50
and 70 years; Ptau ≤ 61 pg/mL [16]. The clinical diagnosis of AD was supported by CSF signature,
consisting of decreased Aβ and increased tau and Ptau levels, according to the criteria of the
International Working Group [2]. Details of the biomarker levels of all participants are provided in
Supplementary Table S1. The Clinical Dementia Rating (CDR), the Mini Mental State Examination
(MMSE), the Frontal Assessment Battery (FAB), the Wisconsin Card Sorting Test (WCST), and the
Tower of London test assessed cognitive dysfunctions. The presence of significant vascular brain
damage was excluded (Hachinski Ischemic Score < 4). Forty plasma samples from sex-matched healthy
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controls (CTRLs) were also collected. All individuals underwent LP in suspicion of a CNS disease
and were discharged with no evidence of neurological diseases and cognitive impairment. None of
them developed cognitive decline over time and, at inclusion, MMSE was ≥28. Whole blood samples,
collected at the time of diagnosis, were allowed to sit at room temperature for a minimum of 30 min
and a max of 2 h, after collection. Separation of the clot was done by centrifugation at 1000–1300× g
at room temperature for 15–20 min. Plasma was removed and dispensed in aliquots of 550 µL into
cryo-tubes and stored at −80 ◦C until use. Informed consent to participate in this study was given by
all subjects or their caregivers. The study was approved by the local ethics committees (Parere 66/2016
Ethics Committee IRCCS Fatebenefratelli and Parere 532_2019bis del 13-6-2019 - Comitato Etico Milano
Area 2).
2.2. Isolation of Total EVs from Plasma
Aliquots of 500 µL of plasma were centrifuged at 3000× g for 15 min to remove cells and debris
The supernatant was transferred to a sterile vessel and incubated with 5 µL of purified thrombin
([500 U/mL], System Biosciences) to a final concentration of 5 U/mL for 5 min at room temperature.
This step is required to remove the large amount of fibrin present in the plasma. After incubation,
samples were centrifuged at 10,000 rpm for 5 min. Supernatants were incubated with 126 µL of
ExoQuick precipitation solution (EXOQ; System Biosciences) and refrigerated for 30 min at 4 ◦C.
The resulting suspension was centrifuged at 1500× g for 30 min at room temperature. The pellet was
then re-suspended in 500 µL of 0.2 µm filtered 1X PBS and conserved at −80 ◦C until use.
2.3. Selective Capture of CD81 and L1CAM-Positive Small Neuronal-Derived EVs (NDEVs) from Plasma with
Magnetic Beads and Sorting of EVs Based on Flow Cytometric (FACS) Analysis
The Exo-Flow Exosome Capture kit (System Biosciences) for the selective capture and flow sorting
of NDEVs purification based on a particular surface marker was used according to the instruction of
the manufacturer. The procedure enables selective capture for immunopurification and flow sorting
to separate the distinct subpopulations of small EVs, based on the L1CAM or CD81 surface marker.
Previously isolated small EVs were resuspended and bound to the magnetic beads for selective
capture and subsequent FACS analysis and sorting. The specific beads involved have 9.1 µm diameter,
a characteristic that enables great vesicle capture.
Supernatants containing the eluted vesicles were carefully removed and transferred to fresh tubes
for further analyses. Supernatants were subjected to sorting by cell sorting (FACSAria SORP and
FACSDiva software, Becton Dickinson, San Josè, CA) and L1CAM NDEVs were selected. In particular,
small NDEVs were identified based on a gating strategy, including a first region on physical properties
and a second one on FITC fluorescence intensity. Specifically, the protocol involves, for each sample and
the negative control, the addition of the bead slurry (40 µL) to 1.5 mL tubes and the further incubation
on a magnetic stand for 2 min. Then they were washed twice. The tubes with bead slurry were removed
from the magnetic stand and 10 µL of mouse anti-human CD171 (L1CAM, neural adhesion protein)
biotinylated capture antibody (clone 5G3, eBioscience) and anti-human CD81 (System Biosciences),
both at a concentration of 100 ng/µL in 1X PBS, were added. After mixing, the tubes were incubated on
ice for 2 h with gentle mixing by flicking every 30 min. The capture antibody-beads were suspended
with 400 µL of wash buffer. The plasma isolated EVs (or PBS for negative control) were added to bead
samples to a final total volume of 500 µL and placed on a rotating shelf at 4 ◦C overnight for capture.
A portion of 240 µL of exosome stain buffer and 10 µL exo-fluorescein isothiocyanate (FITC) exosome
staining solution were added to the beads and incubated on ice for 2 h with gently flicking every
30 min to mix. Samples were washed 3 times in place on the magnetic stand, followed by the addition
of 300 µL wash buffer for FACS analysis, without vortexing. Flow-sort stained EV/bead complexes
were incubated with 300 µL of exosome elution buffer for 40 min at room temperature on a rotating
rack. Finally, the supernatants containing L1CAM positive EVs were obtained.
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2.4. Transmission Electron Microscopy (TEM)
A total of 10 µL of EV-enriched solution was placed on a copper mesh and incubated for 10 min
at room temperature. The grids were then dried by placing them sideways on filter paper and the
EV-enriched fraction was contrasted by using a solution of saturated uranyl acetate in water for
5–10 min. Samples were subsequently dried. The copper mesh was then observed, and pictures
captured with a transmission electron microscope (Leo912ab 80 kv).
2.5. Characterization of Small NDEVs by Nanoparticle Tracking Analysis (NTA)
Suspensions containing total small EVs and small NDEVs from patients and controls were analyzed
using the Nano-Sight NS300 instrument (Malvern, Worcestershire, UK), a laser-based, light-scattering
system which provides a reproducible platform for nanoparticle characterization. Prior to analysis,
samples were diluted in PBS to obtain a range of 20–200 particles in the field of view (particles per frame,
PF). For each sample, 5 videos of 60 s duration were taken. Data were processed using NanoSight NTA
Software 3.2 (Malvern, Worcestershire, UK). The NTA post acquisition settings were optimized and
kept constant between samples. Data obtained were particle size distribution (D-values; D10, D50 and
D90: a particle size value indicating that, respectively, 10%, 50% and 90% of the distribution is below
this value) and concentration (particles/mL).
2.6. Total Plasma EVs Protein Quantification
The protein concentration of total plasma EVs, extracted from two samples, was quantified by Micro
BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA, USA) following the manufacturer’s
specifications and using BSA (ThermoFisher Scientific, Waltham, MA, USA) as a standard. Values were
extrapolated from this curve, using a third-order polynomial equation, with r2 > 0.98 for each assay.
2.7. Western Blotting
We performed Western blotting analysis according to standard protocols. Briefly, EVs were
dissolved in PBS with LDS sample buffer (Life Technologies, Waltham, MA, USA) and separated using
the 4%–12% Bolt Bis-Tris Precast Gels (Life Technologies, Waltham, MA, USA) with MOPS SDS running
buffer (ThermoFisher Scientific, Waltham, MA, USA). Then samples were electro-transferred onto
PVDF membranes (ThermoFisher Scientific, Waltham, MA, USA) for 2 h at 60V at room temperature
and the membranes were immunoblotted with primary antibodies overnight and then incubated with
horseradish peroxidase-conjugated secondary antibodies (1:10,000; Pierce, ThermoFisher Scientific,
Waltham, MA, USA) for 1 h. Immuno-positive bands were detected by enhanced chemiluminescence
(Pierce, Thermo-Fisher Scientific) according to the manufacturer’s instructions. The primary antibodies
anti-L1CAM (1:1000), anti-TSG101 (1:1000) and anti-VPS35 (1:1000) came from Abcam (Cambridge,
MA, USA), and anti-CD9 (1:1000) was purchased from Santa Cruz Biotechnology (Dallas, TEX, USA).
2.8. RNA Extraction from Total and Neural Derived Plasma EVs
Total RNA was extracted by using Total Exosome RNA and Protein Isolation Kit (Thermo
Fisher Scientific, Waltham, MA, USA) that uses Acid-Phenol/Chloroform extraction to provide a
robust front-end RNA purification step, followed by a final RNA purification over a glass-fiber filter.
Ethanol was added to samples that were passed through a Filter Cartridge containing a glass-fiber filter
which immobilizes the RNA. The filter was washed, and the RNA eluted with 30 µL low ionic-strength
solution according to the manufacturer’s instructions.
The RNA from total small EVs was analyzed using Agilent 2100 Bioanalyzer and RNA 6000 Nano
kit (Agilent Technologies, CA, USA) for the determination of RNA concentration, purity, and integrity.
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2.9. Expression Analysis of microRNA by TaqMan OpenArray Human Advanced MicroRNA Panel
Total RNA was reverse transcribed using the TaqMan Advanced miRNA cDNA Synthesis Kit
according to the instructions of the manufacturer (Thermo Fischer Scientific, Waltham, MA, USA).
Given the low RNA amounts obtained from NDEVs, cDNA was preamplified prior to the final real-time
PCR step. The preamplification step was performed using the TaqMan PreAmp Master Mix and pooled
gene-specific primers. The preamplified cDNA (diluted 1:20) was mixed with 2X TaqMan OpenArray
Real-Time Master Mix to perform real-time PCR on the OpenArray plate. A 5 µL sample of PCR
reactions were distributed into each well of 384-well plate and then samples with the master mix were
loaded from the 384-well sample plate onto the OpenArray plate using the OpenArrayAccuFill System.
Finally, PCR was run on the QuantStudio 12K Flex Real-Time PCR System (Thermo Fischer Scientific,
Waltham, MA, USA). For single-tube expression analysis, specific miRNA Advanced TaqMan probes
were used (478532_mir, 477983_mir, 478619_mir, 478358_mir, 478293_mir) according to the instructions
of the manufacturer.
2.10. RNase Treatment and Protection Assay
Small EVs isolated from 4 samples (total plasma and NDEVs) were used for miRNA RNase
protection assay. Three conditions for the same sample were used prior to RNA extraction. The first
condition was EVs treated with 20 mU/mL RNase I in order to eliminate all free circulating RNAs;
the second condition consisted of EVs treated with 20 mU/mL RNase I and 1% TritonX-100 to disrupt
membranes. The third consisted of EVs without treatments used as controls. All samples were
incubated at room temperature for 20 min on a rocking wheel [25,26]. After incubation the RNA was
extracted and the miRNA gene expression assay was carried out as previously described [16].
2.11. Target Gene Prediction and Bioinformatics Analysis
For miRNAs confirmed in the validation phase, target prediction was performed using TargetScan
v 7.1 [27]. DIANA-mirPath was used to perform target prediction and pathway analysis based on two
algorithms, microT-CDS and miRTarBase. The software performs an enrichment analysis of multiple
miRNA target genes to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The graphical
output of the program provides an overview of the parts of the pathway modulated by selected
miRNAs. The statistical significance value associated with the identified biological pathways was
calculated by mirPath [28]. Next, the tissue location of enriched expression for targets was determinate
using FunRich v.3.0 (www.funrich.org) which combines multiple established databases including
UniProt, Human Protein Atlas, Human Proteome Browser, Human Proteome Map, ProteomicsDB and
Human Proteinpedia to infer regional and cell-type enrichment of target mRNAs for a given list of
miRNAs [29].
2.12. Normalization and Statistical Analyses
Exploratory data analysis was performed using ClustVis (https://biit.cs.ut.ee/clustvis/).
Normalized delta Cq-values (dCq) were used for clustering analysis based on Euclidean distance
and complete linkage. Unit variance row scaling was applied for hierarchical clustering and principal
component analysis (PCA) [30,31].
Results from the real time PCR will be calculated as Fold-Change [2ˆ(-∆∆Ct)], which is the
normalized gene expression [2ˆ(-∆Ct)] in the AD group divided by the normalized gene expression
[2ˆ(-∆Ct)] in the control group.
GraphPad Prism 6.0 software (San Diego, CA, USA) was used for statistical analysis. Fisher’s exact
test and the student’s t-test were used to compare gender and age distribution. Test of normality
was performed by using the Shapiro−Wilk’s test. Subsequently, comparisons of ncRNAs levels,
expressed by relative quantification (RQ), between patients and controls were performed by using
the nonparametric Mann−Whitney test and the correction for multiple comparisons was performed
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using the post hoc Dunn’s test. The selection of miRNAs for normalization was performed using the
algorithm NormFinder. From this, the spike-in cel-miR-39 as well as miR-20b-5p and miR-21-5p were
used to normalize across all Ct values using a combined geometric mean of all three Ct values [32].
2.13. Availability of Data and Materials
All data relevant to the study are included in the article or as supplementary information.
Upon reasonable request, additional information (e.g., protocols) will be shared by the corresponding author.
2.14. Ethics Approval and Consent to Participate
All subjects gave written consent and agreed to be in the study, and biological specimens
were obtained after consent with approval of local CE: Parere 66/2016 Ethics Committee IRCCS
Fatebenefratelli and Parere 532_2019bis del 13-6-2019 - Comitato Etico Milano Area 2.
3. Results
3.1. Characterization of Total and L1CAM Positive EVs from Plasma
A population consisting of 40 AD patients and 40 healthy controls (CTRLs) was investigated.
The study was structured as follows: (1) discovery phase involving 20 AD patients and 20 CTRLs
tested for 754 candidate miRNAs and (2) validation phase, involving the remaining 20 AD samples
and 20 controls, for the validation of previously determined best hits miRNAs.
Participants’ demographic and clinical information are summarized in Table 1. Small EVs fractions
were characterized for the presence of specific surface markers, size, morphology with three different
experiments as suggested by the ISEV [3]. Initially, the size of the plasma derived EVs, including the
neural-derived fraction, was evaluated with NTA, then different vesicle markers were tested by Western
blotting. Additionally, TEM analysis for total and small neural-derived EVs was performed.
Table 1. Characteristics of patients and controls.
AD CTRLs
Number of subjects 40 40
Gender (M:F) 15:25 * 22:18 *
Mean age at blood 72.8 66.6
sampling (years ±SD) 2.8 ** 5.1 **
Mean Aβ-42 (pg/mL) 510.56 804.98
Mean h-tau (pg/mL) 648.97 548.22
Mean p-tau (pg/mL) 86 74
SD = Standard Deviation. * p = 0.065; ** p < 0.001.
NTA confirmed that the total EV suspensions were enriched in small EVs. In particular,
NTA revealed the following size distribution (mean ± SD): D10: 70 ± 1.3 nm; D50: 97 ± 1.9 nm;
D90: 196 ± 9.9 nm with a particle concentration of 6.7 ± 0.8 × 1011 particles/mL); the negative control
was undetectable, i.e., below the detection limit of the instrument, thus not interfering with the sample
analysis (Figure 1). The protein concentration of the total plasma EVs was also evaluated in two
samples, and an EV-associated protein concentration of 189.67 ± 98.2 µg/mL was reported. The ratio of
particle counts and protein concentration as described by Webber and Clayton, 2013, was calculated,
in order to test the quality of the purification process [33]. A ratio of 3.5 × 109 p/µg was obtained
suggesting good purity of the total plasma EV preparations [33].
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the morphology of EVs isolated from fresh samples (e) compared with frozen ones (f). Western blot
analysis. L1CAM, CD9, VPS35, TSG101 markers were all detected in the NDEVs enriched fraction of
plasma samples (g).
TEM rev aled a homogenous population of morphologically distinctive particles, mainly oval-shaped,
approximately 150 nm in diameter of EVs labeled with anti-CD81, known as general small vesicle
marker, and L1CAM marker (Figure 2c,d). Furthermore, we did not find substantial differences in
the morphology of EVs isolated from fresh samples (e) compared with frozen ones (f). Western blot
analysis confirmed the presence of the neural marker L1CAM in the extracted vesicle subpopulation.
As shown in Figure 2g, we found NDEVs immunoreactivity for both L1CAM and the common vesicle
markers CD9, Tsg101 and the protein retromer Vps35.
3.2. MiRNAs Expression Profile in Total Plasma EVs and NDEVs in AD Patients and Healthy Subjects
RNA from total plasma EVs and NDEVs was initially isolated from 20 AD samples and
20 controls and the quality and size of extracted RNA were verified by bioanalyzer (Supplementary
Figure S2). Thereafter, miRNAs were profiled by RT-qPCR using the TaqMan Open Array miRNA
panel, which enables the testing of 754 human miRNAs. Raw data underwent quality control measures.
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Applying a Crt cutoff < 28 and the amp score > 1 (measures of good amplification quality), a total
of 57 miRNAs were detected across all 40 samples (Supplementary Table S2). For the normalization,
Crt values of spike-in cel-miR-39 and miR-20b-5p along with the endogenous miR-21-5p were combined
to generate the geometric mean using the available protocol of Andersen [32]. A specific distribution
of miRNA expression was observed for both the EV populations analyzed, although there was an
overlap for some miRNA expression between the fractions. The most variable miRNAs in the total EVs
(Figure 3) and NDEV (Figure 4) enriched fraction were selected based on the coefficient of variation
and used for principal component analysis (PCA) and hierarchical clustering. These analyses of
all identified miRNAs in both EV fractions revealed that the primary miRNA expression data were
influenced by the disease. In particular, PCA showed a separation of samples based on disease status.
As shown in Figure 5a, 59% of miRNAs expressed was found in total plasma EVs, but not in
NDEVs, 15% overlapped between the two subpopulations and 26% was found only in the NDEVs
(Supplementary Table S2). Specifically, considering the total EVs fraction, increased relative expression
levels (greater than 2.5 fold) of miR-146b-5p, miR-181a-3p, miR-24-3p, miR-125a-5p, let-7b-5p and
miR-27a-5p, miR-185-3p were observed (Figure 3b) in patients versus CTRLs, whereas decreased
relative expression levels (lower than 2.5 fold) of miR-16-5p, miR-15b-5p, miR-30a-5p and miR-204-5p
were detected, although the statistical significance was not reached.
Considering miRNAs detected in NDEVs, a specific signature was observed: miR-1260a, miR-1-3p,
miR-448, miR-628-3p, miR-653-5p, miR-452-3p, miR-502-3p and miR-190a-5p were in fact specifically
detected in the neuronal-derived EVs fraction and an overall upregulation (greater than 2.5 fold) was
observed in patients compared to CTRLs. Moreover, a Mann−Whitney test uncovered a statistically
significant upregulation of miR-23a-3p, miR-223-3p, miR-190-5p (1.16 ± 0.49 versus 7.54 ± 2.5, p = 0.026;
9.32 ± 2.27 versus 0.66 ± 0.18, p < 0.0001; 2.9 ± 1.2 versus 1.93 ± 0.9, p < 0.05, respectively) comparing
AD patients with CTRLs whereas a statistically significant downregulation of miR-100-3p in AD
patients was observed in the same group of EVs (0.069 ± 0.01 versus 0.5 ± 0.1 p < 0.0001, Figure 5b).
In order to confirm the specific vesicle-packed origin of these miRNAs, an RNase protection
assay was performed prior to RNA extraction on the specific miRNAs, miR-223-3p and miR-190a-5p,
miR-23a-3p, previously detected.
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Figure 3. (a) Hiera chical clustering of samples based on microRNA (miRNA) profiles observ d in total
plasma EVs from Alzheimer’s disea e (AD) patients and control subject (CTRLs). The most variant
(according to the coefficient f variation) miRNAs were used for cl stering analysis (Pearson correlation,
average linkage). Rows are centered and unit variance scaling is applied to normalized expression
values. Color indicates relative up- (red) or downregulation for each miRNA (row). (b) Principle
component analysis based on the most variant miRNAs in total plasma EVs.
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Figure 4. (a) Hierarchical clustering of samples based on microRNA (miRNA) profiles observed in
total plasma EVs from AD patients and CTRLs. The most variant (according to coefficient of variation)
miRNAs detected in NDEVs were used for clustering analysis (Pearson correlation, average linkage).
Rows are centered and unit variance scaling is applied to normalized expression values. Color indicates
relative up- (red) or downregulation for each miRNA (row). (b) Principle component analysis based on
the most variant miRNAs in NDEVs.
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Figure 6. RNase protection assay. The miR-223-3p, miR-190-5p and miR-23a-3p were quantified by
q-PCR in total and neural-derived plasma EVs. EVs were treated with or without RNase I and/or Triton
X-100 (n = 4).
Results showed that the miRNAs expression level was slightly decreased by treatment with
RNase I, but it was mostly decreased when detergent was added to disrupt the membranes. These results
suggested that miRNAs were all well protected by the EV membrane in total plasma as well as the
neuronal-derived ones (Figure 6). These data revealed that a significant amount of miR-223-3p,
miR-190a-5p and miR-23a-3p existed in a vesicle associated manner.
To deepen the effective robustness of statistically significant NDEVs’ miRNA expression results
(shown in Figure 5b), a further gene expression analysis of miR-23a-3p, miR-223-3p, miR-190-5p and
miR-100-3p was done on NDEVs extracted from the validation cohort samples consisting of 20 AD
patients and 20 CTRLs.
Significant upregulations of miR-23a-3p, miR-223-3p and miR-190a-5p levels in NDEV from AD
patients as compared with controls were confirmed (p = 0.008; p = 0.016; p = 0.003, respectively) as well
as significant downregulation of miR-100-3p levels (p = 0.008) (Figure 7).
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Figure 7. Relative expression of best dysregulated miRNAs tested in NDEVs from the remaining
20 AD patients and 20 CTRLs (miR-23a-3p ** p = 0.008; miR223-3 * p = 0.016; miR-190a-5p ** p = 0.003;
miR-100-3p ** p = 0.008).
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3.3. miRNA Targets and Pathways Prediction
The differentially deregulated microRNAs in patients were screened for their possible target genes
and biological pathways using the TargetScan v7.1 algorithm. According to the analysis, a total of
1332 mRNA targets for miR-23a-3p, 412 for miR-223-3p, 3168 for miR-100-3p and 224 mRNA targets
for miR-190a-5p were identified. Overlaps between mRNA targets is evident between the combination
of two miRNAs, but no targets are shared among all of them (Figure 8a).
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overlapping specific CNS pathways considering at least three miRNAs, such as the glioma, axon 
guidance, long term depression and calcium signaling ones (Figure 9a). To assess brain region and 
cell-type specific localization of NDEVs miRNAs, the FunRich v.3.0 online available tool was used 
[29]. Results revealed that mRNAs targets were depleted in peripheral blood cells, macrophages and 
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were instead enriched (Figure 9b) 
Figure 8. The miRNA targets and pathways prediction. (a) A 3-set Venn diagram overlap of mRNA
targets statistically deregulated in NDEVs in AD patients (miR-23a-3p, miR-223-3p, miR-100-3p.
and miR-190a-5p. (b) Heatmaps of significant pathways for statistically significant NDEV miRNAs,
predicted by DIANA-miRPath (v.3.0). Pathways are depicted on the x-axis and miRNAs on the y-axis.
The color code represents the log (p-value), with the most significant predicted miRNA-pathway
interactions in red.
Analysis with DIANA-miRpath (v.3.0) showed that combinations of at least two miRNAs
overlapped in path ays such as steroid biosynthesis, proteoglycan in cancers, mTOR signaling and
prion disease pathway (Figure 8b).
For miRNAs specifically detected in NDEVs, the analysis with DIANA-miRpath identified
overlapping specific CNS pathways considering at least three miRNAs, such as the glioma,
axon guidance, long term depression and calcium signaling ones (Figure 9a). To assess brain region and
cell-type specific localization of NDEVs miRNAs, the FunRich v.3.0 online available tool was used [29].
Results revealed that mRNAs targets were depleted in peripheral blood cells, macrophages and red
blood cells, as expected. Notably, the markers of the brain, hippocampus, cortex and cerebellum were
instead enriched (Figure 9b)
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Figure 9. (a) Heatmaps of significant pathways predicted by DIANA- iRPath (v.3.0) for specific
miRNAs detected in NDEVs. Pathways are depicted on the x-axis and miRNAs on the y-axis. The color
code represents the log (p-value), with the most significant predicted miRNA-pathway interactions in
red. (b) Tissue site of expression determined using FunRich v3.0 (http://funrich.org/). The percentage
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Top x-axis is –log10 (p-value) of regional enrichment; bottom x-axis is the percentage of targets
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4. Discussion
Her in, we perfor the firs time a compr hensive characterization of small NDEVs,
an identified a specific AD signature, consisting of sig ifica tly increas d levels of miR-23a-3p,
miR-223-3p, miR-190a-5p and decreased levels of miR-100-3p.
The need for peripheral biomarkers derives fro the invasiveness of the procedure for CSF
collection. In this scenario, NDEVs are candidates for harboring biomarkers reflecting CNS pathogenic
AD alterations.
Recent studies showed that the NDEV enriched fraction represents a powerful reservoir of
biomarkers for the investigation of key molecules involved in the pathogenesis of AD and related
dementias [7–9].
The methodology developed by Fiandaca et al. [7] for the isolation of small NDEVs represents
a modification of the original one published by Mitsuhashi, et al. [34], pioneers in the detection
of exosomes in plasma from specific cellular derivation. The protocol basically involves an
immunochemical enrichment of exosomes from a neural source using cocktails of biotinylated
antibodies and subsequent steps of incubation with streptavidin agarose resin. Despite the published
protocol being successfully applied for the determination of different proteins in neuronal-derived
exosomes, there is still a lack of standardization of the method. Conversely, the methodology herein
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described could be easily approached for the harmonization of a shared protocol among laboratories,
as it is based on the use of commercially available products already proven to isolate exosomes with a
good reliability and to be adaptable to the needs of specific enrichment for a neuronal population of
extracellular vesicles [35]. To provide a complete and objective assessment of this methodology, it is
important to mention that this isolation protocol has an important impact on the quality of isolated
EVs [36], and on the amount of miRNAs obtained from the EVs’ preparation [37].
However, since NTA analysis revealed a significant dimensional heterogeneity among the detected
vesicles, we chose to address them as small EVs as suggested by the MISEV guidelines [3].
Regarding the current data available in literature on specific miRNAs as biomarkers of
neurodegenerative diseases, there is limited evidence of an altered expression of plasma miRNAs in
EVs from AD patients [12,24].
Recently, Chat et al. found miR-212 and miR-132 significantly downregulated in small NDEVs
from AD patients using a relatively small sized SYBR green array based analysis testing 372 miRNA
candidates [38].
However, a comprehensive high throughput miRNA investigation considering either small
NDEVs and the plasma total ones has not been performed so far.
In the current study, for the first time, miRNA content associated to the specific NDEV population
was analyzed, and we showed that miRNA NDEVs’ cargo is different from that deriving from the
overall EV population. Therefore, we identified a specific neuronal signature in peripheral circulation,
likely associated to brain miRNA pathological dysregulations. As expected, due to the low amount
of the specific neural-derived extracellular population and the subsequent relative RNA, only 26%
of miRNAs investigated was reliably detected. All the miRNAs detected were already found in the
extracellular vesicles from human biological samples [39,40]. In particular, miRNAs specifically found
in NDEVs were already reported to be expressed in exosomes isolated from CSF [41].
Despite the finding of several dysregulations, both considering the total amount of vesicles and
the neural-derived fraction, few miRNAs reached the statistical significance threshold. Among those,
miR-23a-3p, miR-223-3p, miR-100-3p and miR-190-5p showed instead a significant dysregulation in
NDEVs from AD patients compared with controls.
Analysis of pathway predictions using bioinformatics tools failed to reveal pathways robustly
disease-correlated common to the four miRNAs, although they were demonstrated to be singularly
involved in specific processes of the CNS such as axon guidance and long-term depression as well as in
neurodegenerative diseases such as AD. A deeper analysis of available literature revealed a long history
of correlation among the investigated miRNAs with dementia. MiR-223 for instance was already
proposed as one of the candidate biomarkers for AD as free circulating as well as contained in serum
exosomes [12,14,42]. In particular, we previously found a significant downregulation of free-circulating
miR-223 and miR-23a levels in serum from AD patients [16]; on the other hand, in the present study,
increased levels of NDEVs miR-223-3p and miR-23a-3p were found in patients compared with controls.
An explanation of these apparently controversial findings could reside in the suggested function of
exosomes as mediators of an active intercellular crosstalk. It is known that exosomes are able to load
miRNAs selectively by a specific process, thus the EVs-derived miRNA profile is prespecified and
not random, and this is related to the fact that EVs induce changes that are preprogrammed in the
host cells [43–45]. In this case, increased levels of miR-223-3p in NDEVs could represent an effort by
neurons to cope with inflammatory events occurring in AD since miR-223-3p is actively involved in
immune response as a negative regulator of inflammation [14].
The same significant trend was found for miR-23a-3p levels in NDEVs; in this case results are
concordant with its upregulated levels found in brain tissue from AD patients, although a reduction
was found, such as free-circulating in serum or in CSF [14,41]. MiR-100-3p levels were found to be
downregulated in NDEVs in patients. Evidence in a murine AD model suggests that the role of miR-100
in Aβ related AD pathogenesis may be related to the “ER stress-miRNAs-mTOR” axis [46]. On the
contrary, no association was reported so far between miR-190a-5p and dementia. However, it was
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already detected in the CSF as free-circulating and, regarding its function, a possible modulation of adult
neurogenesis and in vivo, contextual memory was proposed [47]. Interestingly, miR-190 was involved
in neuroinflammation as its upregulation inhibited the expression of inducible nitric oxide synthase
and other proinflammatory cytokines as IL-6, while it increased the expression of anti-inflammatory
cytokines such as IL-10 in a Parkinson’s disease mouse model. Furthermore, miR-190-5p reduced
neuronal damage and favored the reduction of neuroinflammation in a PD model suggesting an active
role in the disease [48].
As neuroinflammation is a common feature of neurodegenerative disease, miR-190 could act as
a common dementia marker so its exclusive role in AD as biomarker needs to be further clarified.
MiRNAs expression analysis performed with a human miRNA tissue atlas and Funrich v.3.0 revealed
some specific miRNA enrichment in specific brain regions such as the hippocampus, cortex and
cerebellum and depleted in peripheral blood cells, macrophages and red blood cells, highlighting the
relevant role of these miRNAs in brain functions. This miRNA brain-specificity has been nicely
reviewed recently by Herrera-Espejo et al. [20] who highlighted specific deregulation in brain tissue
of seven miRNAs in AD patients. Interestingly, these miRNAs are involved in the regulation of key
pathways, such as axon guidance, longevity, insulin and the MAPK signaling pathway.
Similarly, also miR-223-3p dysregulation seems to be involved in AD pathogenesis by modulating
many other targets involved in differentiation/proliferation (i.e., NFI-A;/EBPbeta, Mef2c) and NF-kB
pathways (i.e., STAT3, IKK). Moreover, it was found to contribute to other CNS diseases such as
Multiple Sclerosis and PD [49,50].
Conversely, miR-23a-3p was found to be synaptically located in adult rat in vivo studies and is a
negative regulator of transcription [51].
Three out of four significantly dysregulated miRNAs had already been detected in the EVs plasma
population, but did not reach the statistical threshold, whereas miR-190a-5p was only detected in the
neural-derived fraction, thus suggesting that miRNAs from plasma EVs and miRNAs from plasma
NDEVs could be considered two different biomarker entities.
In conclusion, the four significant dysregulated miRNAs found in plasma NDEVs were already
detected in the CSF and have some functions or may act in pathways related to the CNS, supporting the
hypothesis of the usefulness to consider these EVs obtained from blood as a source of biomarkers
for CNS pathologies. Given implications with neuroinflammation, it would be worth studying EVs
from microglial origin. Nevertheless, at present there are no reliable extracellular vesicle markers for
microglia [11].
Despite these promising results, some methodological limitations need to be acknowledged.
In particular, the detection of NDEVs is hampered by the small numbers of brain-derived EVs that
are secreted by potentially disease-relevant cells and transported into peripheral blood. These difficulties
are derived from the complexity and technical limitations of current EV isolation methods that could
influence the yield of RNA, also demonstrated by the low numbers of miRNAs detected.
The above mentioned technical limitations could explain the discrepancies between our results
and the ones shown in the recent paper from Cha et al., [38]. The methodologic procedures,
although considering the same L1CAM marker for selecting small NDEVs, were quite different
as well as the criteria for patient selection itself that could represent a limitation as underlined by the
author. Moreover, the authors highlighted the impossibility of completely ruling out the presence of
some plasma RNA outside the vesicles as they did not perform any RNAse protection assay.
All these aspects underline the importance of a standardized procedure and the need for consensus
guidelines for the analysis of RNA derived from specific populations of EVs.
Regarding the population considered for this study, there was a statistically different mean age
at blood sampling between groups. Nevertheless, this cohort derives from a thorough analysis of
all cases who underwent LP in suspicion of neurological disorders and were discharged without
any disease. They were followed up over time (mean 3 years) and no cognitive impairment had
occurred by follow-up, thus likely excluding the development of memory dysfunctions. Given all these
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considerations, a further replication step in a larger independent population is required to confirm this
approach as a specific “window” on the brain. After that, maybe, other miRNAs or non-coding RNAs
molecules could emerge and finally provide a molecular signature with a concrete diagnostic potential.
5. Conclusions
This is the first study that carries out the comparison between a total plasma EVs population
and NDEVs in patients with AD, demonstrating the presence of a specific NDEV miRNA signature.
In particular, significantly increased levels of miR-23a-3p, miR-223-3p, miR-190a-5p and significantly
decreased miR-100-3p levels were observed in NDEVs isolated from AD patients, suggesting a possible
“new peripheral window”, possibly able to reflect pathogenic alterations occurring in the brain.
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